Testosterone as a predictor of pathological stage in clinically localized prostate cancer Journal Article
| Authors: | Isom Batz, G.; Bianco, F. J.; Kattan, M. W.; Mulhall, J. P.; Lilja, H.; Eastham, J. A. |
| Article Title: | Testosterone as a predictor of pathological stage in clinically localized prostate cancer |
| Abstract: | Purpose: Substantial controversy exists in the literature regarding the association between pretreatment testosterone and disease outcome in patients with prostate cancer. We explored the relationship between preoperative total testosterone, and pathological stage and progression in patients with clinically localized prostate cancer treated with radical prostatectomy. Materials and Methods: We retrospectively reviewed the records of consecutive patients with clinically localized prostate cancer treated with radical prostatectomy between January 1990 and June 2003. A total of 326 patients with pretreatment testosterone levels available were eligible for this analysis. Biochemical progression (BCR) was defined by postoperative prostate specific antigen (PSA) greater than 0.4 ng/ml with a confirmatory increase and it occurred in 41 men. No men received adjuvant therapy. Univariate and multivariate logistic regression analyses were done to examine whether pretreatment testosterone was associated with pathological stage. Cox regression was used to assess the association of testosterone and BCR. Results: Median PSA was 6.01 ng/ml (range 0.13 to 86), testosterone was 385 ng/dl (range 133 to 998) and followup was 36 months (range 4 to 136). In 245 patients (75%) disease was organ confined. Lower testosterone correlated with adverse pathological stage on multivariate analysis (p = 0.01), as did clinical stage, biopsy grade and PSA. However, we found no relationship between testosterone and BCR after adjusting for covariates. Furthermore, we found no evidence of an interaction between PSA and testosterone (p = 0.4). Conclusions: On multivariate analysis low preoperative total testosterone was associated with advanced pathological stage but not with BCR. Future studies are warranted with data on more patients who have progressed. Copyright © 2005 by American Urological Association. |
| Keywords: | controlled study; human tissue; retrospective studies; major clinical study; disease course; review; postoperative period; cancer adjuvant therapy; cancer staging; follow-up studies; neoplasm staging; prostate specific antigen; reproducibility of results; neoplasm recurrence, local; statistics; tumor markers, biological; pathology; prediction; outcome assessment (health care); prostate cancer; prostate-specific antigen; prostatic neoplasms; prostate; correlation analysis; prostatectomy; disease progression; prostate biopsy; multivariate logistic regression analysis; multivariate analysis; neoplasm invasiveness; testosterone blood level; regression analysis; testosterone; disease activity |
| Journal Title: | Journal of Urology |
| Volume: | 173 |
| Issue: | 6 |
| ISSN: | 0022-5347 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2005-06-01 |
| Start Page: | 1935 |
| End Page: | 1937 |
| Language: | English |
| DOI: | 10.1097/01.ju.0000158040.33531.e7 |
| PUBMED: | 15879785 |
| PROVIDER: | scopus |
| PMCID: | PMC1855287 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 63" - "Export Date: 24 October 2012" - "CODEN: JOURA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work